At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 34 enrolled
Drug / intervention
Elpipodect +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8189 in Participants With Bipolar I Disorder
In Brief
A Phase 1 clinical trial evaluating Elpipodect and Placebo for Bipolar I Disorder. Completed, enrolled 34 participants across 3 sites.
Detailed Summary
The goal of this study is to evaluate the safety and tolerability of elpipodect in participants with stable bipolar I disorder. There was no hypothesis testing in this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar I Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
First PostedFeb 2024
Enrollment StartApr 2024
Primary CompletionAug 2024
TodayJul 2026
First PostedFeb 23, 2024
Enrollment StartApr 8, 2024
Primary CompletionAug 21, 2024
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.4 years ago
Interventions
Elpipodectdrug
Oral Tablet
Placebodrug
Oral Tablet